A recent study published in the Mayo Clinic Proceedings highlights the benefits of using a combination of statins and ezetimibe for lipid-lowering therapy (LLT) in reducing cardiovascular risks.
Led by Dr. Maciej Banach and co-authored by Dr. Carl J. “Chip” Lavie, Jr. of Ochsner Health, the research analyzed data from over 108,000 high-risk individuals across 14 studies.
The findings indicate that combining statins with ezetimibe significantly lowers LDL cholesterol levels by an average of 12.96 mg/dL compared to statin monotherapy.
This combination therapy also reduces the risk of all-cause mortality by 19%, major adverse cardiovascular events by 18%, and stroke incidence by 17%. Importantly, the safety profile of combination therapy is comparable to statin monotherapy, with similar risks of adverse effects.
The study advocates for early adoption of combination therapy, particularly for high and very high-risk patients, to effectively meet LDL-C targets and substantially reduce mortality and cardiovascular disease events.
By integrating this approach into treatment protocols, clinicians can enhance patient outcomes and contribute to reducing the global burden of cardiovascular disease. Dr. Lavie emphasizes the importance of a proactive strategy in lipid-lowering therapy to optimize LDL-C reductions and improve patient outcomes.
Related topics:
- Study Links Pooping Frequency To Health Risks, Revealing Narrower Optimal Range
- Trump Administration Cuts Climate Health Research Funding
- New Study Reveals Why Back Pain Treatments Often Fall Short
